Asymchem (06821) saw a nearly 3% increase before noon, reaching a 2.05% gain at the time of writing, with its stock price at HKD 79.65 and a trading volume of HKD 15.52 million.

The rise follows the recent announcement that Asymchem's Shanghai Fengxian commercial production base has officially commenced operations. This base is another core commercial facility for Asymchem Bio, following its Shanghai Jinshan base and Zhangjiang Science and Technology Center. It is designed to support clients in accelerating commercial production.

The launch of the Fengxian base marks a significant upgrade for Asymchem Bio in the biologics CDMO sector. The facility spans over 130,000 square meters and focuses on novel drug conjugates (NDCs), including antibody-drug conjugates (ADCs), as well as antibodies/TCEs and recombinant proteins.

The antibody commercial production capacity (Phase I-A) features advanced automation systems and equipment, with 200L/500L/2000L single-use bioreactor production lines and a 20㎡ lyophilizer, capable of handling IND and late-stage commercial projects.

The NDCs commercial production capacity (Phase I-B) is expected to begin operations in January 2026, equipped with 100L-200L-500L conjugation reactors and 10㎡+15㎡+2x20㎡ lyophilizers to flexibly meet client production demands.